Similarly, knocking TRAC region and CD52 gene in CAR-T cells by CRISPR/Cas9 avoided the host immune-mediated rejection for relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (Hu et al., 2021). The gene discussed is CD52; the disease is acute lymphoblastic leukemia.